{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:27:48Z","timestamp":1786973268703,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP 23K24479"],"award-info":[{"award-number":["JP 23K24479"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ijgc.2025.102657","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:11:32Z","timestamp":1757542292000},"page":"102657","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia: a single-center historical cohort study\u2606"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-1644-6289","authenticated-orcid":false,"given":"Eri","family":"Katayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4331-6043","authenticated-orcid":false,"given":"Hirokazu","family":"Usui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoyo","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7328-8198","authenticated-orcid":false,"given":"Rie","family":"Okuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Habu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Nishikimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijgc.2025.102657_bib1","article-title":"First-line chemotherapy in low-risk gestational trophoblastic neoplasia","volume":"2016","author":"Lawrie","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102657_bib2","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1200\/JCO.2002.07.166","article-title":"Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000","volume":"20","author":"McNeish","year":"2002","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102657_bib3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ygyno.2020.05.013","article-title":"An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG\/GOG 275","volume":"158","author":"Schink","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"suppl 2","key":"10.1016\/j.ijgc.2025.102657_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.12615","article-title":"Update on the diagnosis and management of gestational trophoblastic disease","volume":"143","author":"Ngan","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102657_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/gyno.2000.5813","article-title":"Combination chemotherapy with methotrexate, etoposide, and actinomycin D for high-risk gestational trophoblastic tumors","volume":"78","author":"Matsui","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102657_bib6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ygyno.2004.11.011","article-title":"Relapse rate of patients with low-risk gestational trophoblastic tumor initially treated with single-agent chemotherapy","volume":"96","author":"Matsui","year":"2005","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2025.102657_bib7","unstructured":"U.S. Department of Health and Human Services. (2017). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute. Retrieved October 4, 2025, from https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102657_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijgo.2011.08.003","article-title":"Comparison of pulsed actinomycin D versus 5-day methotrexate for the treatment of low-risk gestational trophoblastic disease","volume":"116","author":"Mousavi","year":"2012","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102657_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1006\/gyno.1994.1169","article-title":"5-day methotrexate for women with metastatic gestational trophoblastic disease","volume":"54","author":"Soper","year":"1994","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102657_bib10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ygyno.2007.09.006","article-title":"Treatment for low-risk gestational trophoblastic disease: comparison of single-agent methotrexate, dactinomycin and combination regimens","volume":"108","author":"Abr\u00e3o","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102657_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11684-021-0855-4","article-title":"Chemotherapy initiation with single-course methotrexate alone or combined with dactinomycin versus multi-course methotrexate for low-risk gestational trophoblastic neoplasia: a multi-centric randomized clinical trial","volume":"16","author":"Chen","year":"2022","journal-title":"Front Med"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102657_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1479-828X.2005.00366.x","article-title":"Comparison of pulse methotrexate and pulse dactinomycin in the treatment of low-risk gestational trophoblastic neoplasia","volume":"45","author":"Gilani","year":"2005","journal-title":"Aust N Z J Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102657_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijgo.2008.05.013","article-title":"Pulse methotrexate versus pulse actinomycin D in the treatment of low-risk gestational trophoblastic neoplasia","volume":"103","author":"Yarandi","year":"2008","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102657_bib14","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","article-title":"Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study","volume":"29","author":"Osborne","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102657_bib15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1186\/s12885-018-4512-5","article-title":"Pulse actinomycin D as first-line treatment of low-risk post-molar non-choriocarcinoma gestational trophoblastic neoplasia","volume":"18","author":"Li","year":"2018","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102657_bib16","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/IGC.0000000000000687","article-title":"Five-day intravascular methotrexate versus biweekly actinomycin-D in the treatment of low-risk gestational trophoblastic neoplasia: a clinical randomized trial","volume":"26","author":"Yarandi","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"25","key":"10.1016\/j.ijgc.2025.102657_bib17","first-page":"00811","article-title":"Efficacy and safety of biweekly single-dose actinomycin D versus multiday methotrexate in low-risk gestational trophoblastic neoplasia: a prospective multicenter randomized trial","volume":"S0923-7534","author":"Jiang","year":"2025","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102657_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1089\/gtmb.2016.0326","article-title":"Association between MTHFR C677T polymorphism and methotrexate treatment outcome in rheumatoid arthritis patients: a systematic review and meta-analysis","volume":"21","author":"Shao","year":"2017","journal-title":"Genet Test Mol Biomarkers"},{"key":"10.1016\/j.ijgc.2025.102657_bib19","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ejphar.2016.11.010","article-title":"Presence of the methylenetetrahydrofolate reductase gene polymorphism MTHFR C677T in molar tissue but not maternal blood predicts failure of methotrexate treatment for low-risk gestational trophoblastic neoplasia","volume":"794","author":"Qu","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102657_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ygyno.2011.08.012","article-title":"667C>T and 1298A>C polymorphisms of MTHFR do not predict response to methotrexate in patients with gestational trophoblastic neoplasia","volume":"123","author":"Lasecka","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102657_bib21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2015.04.030","article-title":"Relationship between race and clinical characteristics, extent of disease, and response to chemotherapy in patients with low-risk gestational trophoblastic neoplasia","volume":"138","author":"Maest\u00e1","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102657_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ijgo.12629","article-title":"Comparison of pulsed actinomycin D and 5-day actinomycin D as first-line chemotherapy for low-risk gestational trophoblastic neoplasia","volume":"143","author":"Mu","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102657_bib23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/IGC.0b013e3181a8333d","article-title":"Actinomycin D versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial","volume":"19","author":"Lertkhachonsuk","year":"2009","journal-title":"Int J Gynecol Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25017773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25017773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:58:47Z","timestamp":1786971527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25017773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1048891X25017773"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102657","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of the efficacy and safety of five-day methotrexate versus pulse actinomycin D for low-risk gestational trophoblastic neoplasia: a single-center historical cohort study\u2606","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102657","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102657"}}